News

European Initiative Targets Diagnosis, Treatment of Rare Diseases

A new international consortium based in Paris, and funded largely by the 28-member European Union, intends to speed the diagnosis of rare diseases, while also accelerating the development of treatments for the 95% of such illnesses that currently don’t have one. The European Joint Programme on Rare Diseases (EJP…

Ra Pharma and Camurus Agree to Develop Extended-release Formulation of Zilucoplan

Camurus AB and Ra Pharmaceuticals have signed an agreement to develop and manufacture a long-acting injectable formulation of zilucoplan for patients with complement-mediated disorders, such as generalized myasthenia gravis. Using Camurus’s proprietary FluidCrystal technology, the subcutaneously injected formulation will allow patients with complement-mediated disorders — such as…

NORD Honors Industry, Patient Advocates at Rare Impact Awards Gala

A violinist with vasculitis, two Texas politicians and a pharmaceutical company whose marijuana-derived therapy helps kids with Dravet syndrome were among winners of the 2019 Rare Impact Awards. Officials of the National Organization for Rare Disorders (NORD) presented the awards during a June 22 dinner attended by…